Christian Pott
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christian Pott has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Lars Eckardt
Division of Electrophysiology, Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany
8 shared publicationsGerold Mönnig
Division of Electrophysiology, Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany
6 shared publicationsKristina Wasmer
Division of Electrophysiology, Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany
5 shared publicationsStephan Zellerhoff
Division of Electrophysiology, Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany
5 shared publicationsDirk G. Dechering
Division of Electrophysiology, Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany
4 shared publicationsJulia Köbe
Division of Electrophysiology, Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany
4 shared publications
Latest Publications
- Open Access
- 25 March 2016
- Published by Elsevier in Journal of Cardiology
- Vol. 69 (2) , 471-475
Slow pathway modification in patients presenting with only two consecutive AV nodal echo beats
- 25 March 2016
- Published by Elsevier in Journal of Cardiology
- Vol. 69 (2) , 471-475
Open AccessSlow pathway modification in patients presenting with only two consecutive AV nodal echo beats
- 24 February 2016
- Published by Elsevier in Heart Rhythm
- Vol. 13 (8) , 1596-1601
Lower rate of left atrial tachycardia after pulmonary vein isolation with PVAC versus irrigated-tip circumferential antral ablation
- 24 February 2016
- Published by Elsevier in Heart Rhythm
- Vol. 13 (8) , 1596-1601
Lower rate of left atrial tachycardia after pulmonary vein isolation with PVAC versus irrigated-tip circumferential antral ablation
- 21 May 2015
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 104 (11) , 946-954
Outcome predictors of empirical slow pathway modulation: clinical and procedural characteristics and long-term follow-up
Catheter-based modulation of the slow pathway is the first-line therapy of atrioventricular nodal reentrant tachycardia (AVNRT), the most common supraventricular tachycardia (SVT). In patients with a typical history, in whom AVNRT is not inducible during an electrophysiological study, the current guidelines allow consideration of empirical slow pathway modulation (ESPM) under the precondition that both, dual nodal pathway physiology (DNPP) and an ECG documentation compatible with AVNRT exist. This recommendation is based on small series. Furthermore, it is unknown whether ESPM is beneficial in the presence of ECG documentation but the absence of DNPP or vice versa in the presence of DNPP but absence of ECG documentation. Out of 3003 patients who underwent slow pathway modulation from 1993 to 2013, we included 116 patients (68 female; median age 47.0 years) with symptomatic tachycardia who had non-inducible SVT. All patients either had ECG documentation of SVT (66 %) or DNPP (89 %) or both (54 %). All patients underwent ESPM. No severe complications occurred. After a follow-up time of 64 ± 5.3 months, 81 % of all patients had benefited from ESPM (49 % freedom of symptoms, 32 % improvement). In patients with ECG documentation but absence of DNPP 100 % benefited (85 % freedom of symptoms; 15 % improvement). In patients with DNPP but absence of ECG documentation 75 % benefited (40 % freedom of symptoms, 35 % improvement). In a large cohort of patients, ESPM is a safe procedure that improves clinical symptoms in the majority of patients during long-term follow-up. We show for the first time that this also applies for cases where there is no DNPP but a characteristic ECG documentation, and vice versa.
- 21 May 2015
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 104 (11) , 946-954
Outcome predictors of empirical slow pathway modulation: clinical and procedural characteristics and long-term follow-up
Catheter-based modulation of the slow pathway is the first-line therapy of atrioventricular nodal reentrant tachycardia (AVNRT), the most common supraventricular tachycardia (SVT). In patients with a typical history, in whom AVNRT is not inducible during an electrophysiological study, the current guidelines allow consideration of empirical slow pathway modulation (ESPM) under the precondition that both, dual nodal pathway physiology (DNPP) and an ECG documentation compatible with AVNRT exist. This recommendation is based on small series. Furthermore, it is unknown whether ESPM is beneficial in the presence of ECG documentation but the absence of DNPP or vice versa in the presence of DNPP but absence of ECG documentation. Out of 3003 patients who underwent slow pathway modulation from 1993 to 2013, we included 116 patients (68 female; median age 47.0 years) with symptomatic tachycardia who had non-inducible SVT. All patients either had ECG documentation of SVT (66 %) or DNPP (89 %) or both (54 %). All patients underwent ESPM. No severe complications occurred. After a follow-up time of 64 ± 5.3 months, 81 % of all patients had benefited from ESPM (49 % freedom of symptoms, 32 % improvement). In patients with ECG documentation but absence of DNPP 100 % benefited (85 % freedom of symptoms; 15 % improvement). In patients with DNPP but absence of ECG documentation 75 % benefited (40 % freedom of symptoms, 35 % improvement). In a large cohort of patients, ESPM is a safe procedure that improves clinical symptoms in the majority of patients during long-term follow-up. We show for the first time that this also applies for cases where there is no DNPP but a characteristic ECG documentation, and vice versa.
- 1 August 2014
- Published by Elsevier in International Journal of Cardiology
- Vol. 175 (2) , 366-367
Response to the letter regarding article “A patient series of dual atrioventricular nodal nonreentrant tachycardia (DAVNNT) - An often overlooked diagnosis?”
- 1 August 2014
- Published by Elsevier in International Journal of Cardiology
- Vol. 175 (2) , 366-367
Response to the letter regarding article “A patient series of dual atrioventricular nodal nonreentrant tachycardia (DAVNNT) - An often overlooked diagnosis?”
- 31 March 2014
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 21 (11) , 1330-1335
Advantages and Limitations of Transgenic Mice: The Role of the Na+/Ca2+ Exchanger in Cardiac Electrophysiology and Arrhythmia
In the search for novel antiarrhythmic strategies, the cardiac Na+/Ca2+ exchanger (NCX) seems to be a promising target. Recent insights into the role of NCX in proarrhythmia stem from transgenic murine models with knockout or overexpression of NCX. There are significant differences regarding cellular electrophysiology, excitation-contraction coupling and Ca2+ handling when comparing mice to higher mammal and most importantly human physiology. We here review findings derived from transgenic mouse models regarding the role of NCX in the generation of arrhythmia and discuss principle aspects to consider when translating physiological and pathophysiological mechanisms from mouse models into human physiology and the clinical context.
- 31 March 2014
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 21 (11) , 1330-1335
Advantages and Limitations of Transgenic Mice: The Role of the Na+/Ca2+ Exchanger in Cardiac Electrophysiology and Arrhythmia
In the search for novel antiarrhythmic strategies, the cardiac Na+/Ca2+ exchanger (NCX) seems to be a promising target. Recent insights into the role of NCX in proarrhythmia stem from transgenic murine models with knockout or overexpression of NCX. There are significant differences regarding cellular electrophysiology, excitation-contraction coupling and Ca2+ handling when comparing mice to higher mammal and most importantly human physiology. We here review findings derived from transgenic mouse models regarding the role of NCX in the generation of arrhythmia and discuss principle aspects to consider when translating physiological and pathophysiological mechanisms from mouse models into human physiology and the clinical context.
- 1 March 2014
- Published by Elsevier in International Journal of Cardiology
- Vol. 172 (1) , e9-e11
A patient series of dual atrioventricular nodal nonreentrant tachycardia (DAVNNT) — An often overlooked diagnosis?
- 1 March 2014
- Published by Elsevier in International Journal of Cardiology
- Vol. 172 (1) , e9-e11
A patient series of dual atrioventricular nodal nonreentrant tachycardia (DAVNNT) — An often overlooked diagnosis?
- 18 July 2012
- Published by Springer Nature in Wiener Medizinische Wochenschrift
- Vol. 162 (13-14) , 277
Calcium is omnipresent in the physiology and pathophysiology of heart disease
- 18 July 2012
- Published by Springer Nature in Wiener Medizinische Wochenschrift
- Vol. 162 (13-14) , 277
Calcium is omnipresent in the physiology and pathophysiology of heart disease
- 11 February 2012
- Published by Springer Nature in Basic Research in Cardiology
- Vol. 107 (2) , 1-13
Proarrhythmia in a non-failing murine model of cardiac-specific Na+/Ca2+ exchanger overexpression: whole heart and cellular mechanisms
The cardiac Na+/Ca2+ exchanger (NCX) generates an inward electrical current during SR-Ca2+ release, thus possibly promoting afterdepolarizations of the action potential (AP). We used transgenic mice 12.5 weeks or younger with cardiomyocyte-directed overexpression of NCX (NCX-Tg) to study the proarrhythmic potential and mechanisms of enhanced NCX activity. NCX-Tg exhibited normal echocardiographic left ventricular function and heart/body weight ratio, while the QT interval was prolonged in surface ECG recordings. Langendorff-perfused NCX-Tg, but not wild-type (WT) hearts, developed ventricular tachycardia. APs and ionic currents were measured in isolated cardiomyocytes. Cell capacitance was unaltered between groups. APs were prolonged in NCX-Tg versus WT myocytes along with voltage-activated K+ currents (Kv) not being reduced but even increased in amplitude. During abrupt changes in pacing cycle length, early afterdepolarizations (EADs) were frequently recorded in NCX-Tg but not in WT myocytes. Next to EADs, delayed afterdepolarizations (DAD) triggering spontaneous APs (sAPs) occurred in NCX-Tg but not in WT myocytes. To test whether sAPs were associated with spontaneous Ca2+ release (sCR), Ca2+ transients were recorded. Despite the absence of sAPs in WT, sCR was observed in myocytes of both genotypes suggesting a facilitated translation of sCR into DADs in NCX-Tg. Moreover, sCR was more frequent in NCX-Tg as compared to WT. Myocardial protein levels of Ca2+-handling proteins were not different between groups except the ryanodine receptor (RyR), which was increased in NCX-Tg versus WT. We conclude that NCX overexpression is proarrhythmic in a non-failing environment even in the absence of reduced KV. The underlying mechanisms are: (1) occurrence of EADs due to delayed repolarization; (2) facilitated translation from sCR into DADs; (3) proneness to sCR possibly caused by altered Ca2+ handling and/or increased RyR expression.
- 11 February 2012
- Published by Springer Nature in Basic Research in Cardiology
- Vol. 107 (2) , 1-13
Proarrhythmia in a non-failing murine model of cardiac-specific Na+/Ca2+ exchanger overexpression: whole heart and cellular mechanisms
The cardiac Na+/Ca2+ exchanger (NCX) generates an inward electrical current during SR-Ca2+ release, thus possibly promoting afterdepolarizations of the action potential (AP). We used transgenic mice 12.5 weeks or younger with cardiomyocyte-directed overexpression of NCX (NCX-Tg) to study the proarrhythmic potential and mechanisms of enhanced NCX activity. NCX-Tg exhibited normal echocardiographic left ventricular function and heart/body weight ratio, while the QT interval was prolonged in surface ECG recordings. Langendorff-perfused NCX-Tg, but not wild-type (WT) hearts, developed ventricular tachycardia. APs and ionic currents were measured in isolated cardiomyocytes. Cell capacitance was unaltered between groups. APs were prolonged in NCX-Tg versus WT myocytes along with voltage-activated K+ currents (Kv) not being reduced but even increased in amplitude. During abrupt changes in pacing cycle length, early afterdepolarizations (EADs) were frequently recorded in NCX-Tg but not in WT myocytes. Next to EADs, delayed afterdepolarizations (DAD) triggering spontaneous APs (sAPs) occurred in NCX-Tg but not in WT myocytes. To test whether sAPs were associated with spontaneous Ca2+ release (sCR), Ca2+ transients were recorded. Despite the absence of sAPs in WT, sCR was observed in myocytes of both genotypes suggesting a facilitated translation of sCR into DADs in NCX-Tg. Moreover, sCR was more frequent in NCX-Tg as compared to WT. Myocardial protein levels of Ca2+-handling proteins were not different between groups except the ryanodine receptor (RyR), which was increased in NCX-Tg versus WT. We conclude that NCX overexpression is proarrhythmic in a non-failing environment even in the absence of reduced KV. The underlying mechanisms are: (1) occurrence of EADs due to delayed repolarization; (2) facilitated translation from sCR into DADs; (3) proneness to sCR possibly caused by altered Ca2+ handling and/or increased RyR expression.
- 1 May 2011
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 12 (5) , 737-747
Triple Threat: The Na+/Ca2+ Exchanger in the Pathophysiology of Cardiac Arrhythmia, Ischemia and Heart Failure
The Na+/Ca2+ exchanger (NCX) is the main Ca2+ extrusion mechanism of the cardiac myocyte and thus is crucial for maintaining Ca2+ homeostasis. It is involved in the regulation of several parameters of cardiac excitation contraction coupling, such as cytosolic Ca2+ concentration, repolarization and contractility. Increased NCX activity has been identified as a mechanism promoting heart failure, cardiac ischemia and arrhythmia. Transgenic mice as well as pharmacological interventions have been used to support the idea of using NCX inhibition as a future pharmacological strategy to treat cardiovascular disease.
- 1 May 2011
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 12 (5) , 737-747
Triple Threat: The Na+/Ca2+ Exchanger in the Pathophysiology of Cardiac Arrhythmia, Ischemia and Heart Failure
The Na+/Ca2+ exchanger (NCX) is the main Ca2+ extrusion mechanism of the cardiac myocyte and thus is crucial for maintaining Ca2+ homeostasis. It is involved in the regulation of several parameters of cardiac excitation contraction coupling, such as cytosolic Ca2+ concentration, repolarization and contractility. Increased NCX activity has been identified as a mechanism promoting heart failure, cardiac ischemia and arrhythmia. Transgenic mice as well as pharmacological interventions have been used to support the idea of using NCX inhibition as a future pharmacological strategy to treat cardiovascular disease.
- 2 February 2011
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 13 (6) , 897-901
Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmogenic disease that can cause sudden cardiac death due to ventricular fibrillation (VF). While pharmacological therapy with beta-blockers and/or Ca2+ antagonists is often unreliable, a recent study has demonstrated that flecainide can effectively suppress arrhythmia in a murine model of CPVT as well as clinically in two human subjects suffering from CPVT. We here present the case of an 11-year-old boy suffering from CPVT-1 as well as a review of the current relevant literature. After resuscitation due to VF at age 9, an automated implantable cardioverter–defibrillator (ICD) was implanted in 2007. Under beta-blocker therapy, repeated shocks were delivered due to either fast ventricular tachycardia (VT) or VF. This persisted under additional therapy with verapamil. Implantable cardioverter–defibrillator routine interrogations showed frequent non-sustained VT with an average of 8.8 per day. Additionally, the patient suffered from impaired physical performance due to decreased chronotropic competence. In July 2009, flecainide was added to the beta-blocker/verapamil regimen, resulting in a plasma level of 0.20 mg/L. No ICD shock or sustained VT occurred until December 2010. Genetic testing revealed an RyR2 receptor mutation. The case demonstrates the challenge of diagnosis and management of CPVT. It furthermore supports recent experimental evidence that the class 1 antiarrhythmic drug flecainide can suppress CPVT. The presented case supports a novel strategy in treating CPVT with the class I antiarrhythmic agent flecainide.
- 2 February 2011
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 13 (6) , 897-901
Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmogenic disease that can cause sudden cardiac death due to ventricular fibrillation (VF). While pharmacological therapy with beta-blockers and/or Ca2+ antagonists is often unreliable, a recent study has demonstrated that flecainide can effectively suppress arrhythmia in a murine model of CPVT as well as clinically in two human subjects suffering from CPVT. We here present the case of an 11-year-old boy suffering from CPVT-1 as well as a review of the current relevant literature. After resuscitation due to VF at age 9, an automated implantable cardioverter–defibrillator (ICD) was implanted in 2007. Under beta-blocker therapy, repeated shocks were delivered due to either fast ventricular tachycardia (VT) or VF. This persisted under additional therapy with verapamil. Implantable cardioverter–defibrillator routine interrogations showed frequent non-sustained VT with an average of 8.8 per day. Additionally, the patient suffered from impaired physical performance due to decreased chronotropic competence. In July 2009, flecainide was added to the beta-blocker/verapamil regimen, resulting in a plasma level of 0.20 mg/L. No ICD shock or sustained VT occurred until December 2010. Genetic testing revealed an RyR2 receptor mutation. The case demonstrates the challenge of diagnosis and management of CPVT. It furthermore supports recent experimental evidence that the class 1 antiarrhythmic drug flecainide can suppress CPVT. The presented case supports a novel strategy in treating CPVT with the class I antiarrhythmic agent flecainide.